Latest studies
- RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
DLBCLDiffuse Large B-Cell LymphomaHong Kong - RecruitingPHASE1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
This study is looking at a new drug, RO7673396, for advanced cancers with a specific gene change (RAS mutation). We want to check if it's safe and how the body handles it. We'll also see if it helps shrink tumors.
NeoplasmsHong Kong - Active not recruiting
Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System
This study looks at how safe and effective a new treatment called FARAPULSE is for atrial fibrillation. It collects real-world information about people treated with this system in hospitals to see how well it works and if it improves their quality of life.
Atrial FibrillationHong Kong - Active not recruitingNA
ASCEND CSP IDE Study
This study is testing a new type of heart device lead for people with heart failure. It looks at how safe and effective the "CSP ICD Lead" is when used with special heart devices to help control irregular heartbeats and improve heart function.
Heart FailureVentricular ArrythmiaHong Kong - Active not recruitingPHASE1
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
This study looks at a new drug, KFA115, on its own and with another drug, pembrolizumab, for various advanced cancers. It aims to find a safe and effective dose, helping doctors understand how these treatments work.
Carcinoma, Non-Small-Cell LungCutaneous MelanomaCarcinoma, Renal CellCarcinoma, Ovarian EpithelialHong Kong - Active not recruitingPHASE1
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
This study, called MTAPESTRY 104, is testing a new drug called Anvumetostat, alone or with other treatments, for advanced lung cancers that have a specific genetic change (MTAP-deletion). It aims to find the safest and most effective dose.
Thoracic TumorsNon-small Cell Lung CancerHong Kong - Active not recruitingPHASE3
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
This study looks at a new drug, DB-1303/BNT323, for advanced breast cancer that's 'HER2-low' and hormone-positive. It compares the new drug to standard chemotherapy to see if it can stop the cancer from growing for longer.
Metastatic Breast CancerHong Kong - Active not recruitingPHASE3
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
This study is looking at a new combination of medicines, belrestotug and dostarlimab, for people with a certain type of lung cancer that hasn't been treated before. It compares this combination to a standard treatment (pembrolizumab) and a dummy drug (placebo).
Lung Cancer, Non-Small CellHong Kong - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This study looks at new drug combinations for advanced liver cancer that hasn't been treated before. It compares cabozantinib with atezolizumab against a standard treatment, sorafenib, to see which works better and is safer.
Hepatocellular CarcinomaHong Kong - Enrolling by invitationPHASE3
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
This study is checking how people who previously received a treatment called delandistrogene moxeparvovec for Duchenne muscular dystrophy are doing over time. Researchers want to see if the treatment is safe and effective in the long run. No new treatment will be given during this study.
Duchenne Muscular DystrophyHong Kong - Active not recruitingPHASE3
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
This study is testing new treatments for liver cancer (hepatocellular carcinoma) in people who have had their cancer removed but are at high risk of it coming back. It compares a drug called durvalumab, alone or with bevacizumab, against a dummy treatment (placebo) to see if they can prevent the cancer from returning.
Hepatocellular CarcinomaHong Kong - Not yet recruitingPHASE2
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
This study looks at a new combination treatment for advanced bowel cancer that has spread. It combines a new drug, VVD-133214, with an existing immunotherapy, pembrolizumab. The aim is to see if this combination works better than pembrolizumab alone for certain types of bowel cancer.
Colorectal AdenocarcinomaHong Kong - RecruitingPHASE3
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
This study is testing new ways to treat advanced bowel cancer (colorectal cancer) that has spread to other parts of the body. It compares a new drug, Precem-TcT, alone or with another treatment called bevacizumab, against a standard treatment, to see which works best.
Metastatic Colorectal CancerHong Kong - RecruitingPHASE3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
This study looks at a new drug, zilovertamab vedotin, combined with standard treatment for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). Researchers want to see if this new combination helps people live longer without their cancer growing or spreading, compared to standard treatment alone.
Diffuse Large B-Cell LymphomaHong Kong - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
Colon AdenocarcinomaRectal AdenocarcinomaHong Kong - RecruitingPHASE3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
This study looks at how safe and effective a medicine called mezagitamab is for adults with a bleeding condition called ITP. If you’ve been in a previous mezagitamab study, you might be invited to join this longer follow-up.
Immune Thrombocytopenic Purpura (ITP)Hong Kong - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseHong Kong - RecruitingPHASE3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
This study looks at the long-term safety and effectiveness of a new medicine, marstacimab, for people with haemophilia A or B. It includes patients who already took part in earlier studies of this medicine.
Hemophilia AHemophilia BHong Kong - Not yet recruitingPHASE2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This study is for people with advanced solid tumours that have a specific genetic change called an MTAP deletion. It's testing a new medicine, BMS-986504, alone and with other cancer treatments, to see how safe and effective they are.
Solid TumorsHong Kong - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerHong Kong - Recruiting
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
This study is for adults in the UK who have previously taken part in a trial for a liver condition called chronic hepatitis B, and who were treated with a medicine called imdusiran. It looks at their health over the long term after stopping treatment, without giving them new medicines.
Long Term Follow-upHong Kong - Active not recruitingPHASE3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This study allows some cancer patients who are already benefiting from certain treatments in another study to continue receiving that treatment. It’s for those who wouldn't be able to get the treatment otherwise, helping them keep accessing therapies that are working for them.
CancerHong Kong - Active not recruitingPHASE4
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
This study offers ongoing access to ceritinib for patients already benefiting from it in another Novartis study. It's for people with ALK-positive cancers who, along with their doctor, believe continued treatment is helping them.
ALK Positive MalignanciesHong Kong - RecruitingNA
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
This study looks at a new way to treat a type of irregular heartbeat called persistent atrial fibrillation. It compares two methods of a treatment called pulsed field ablation to see if one is safer and works better at stopping the heart from beating irregularly.
Atrial Fibrillation (AF)Persistant Atrial FibrillationHong Kong - Active not recruitingPHASE3
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
This study looks at two drugs, durvalumab and tremelimumab, as a first treatment for advanced liver cancer that can't be removed by surgery. Researchers want to see how safe and effective this combination is.
Advanced Hepatocellular CarcinomaHong Kong - RecruitingPHASE1, PHASE2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
This study is looking at a new drug called repotrectinib for advanced cancers that have specific gene changes (ALK, ROS1, or NTRK). It aims to find the best dose and see how well it works in shrinking tumours and how safe it is.
Locally Advanced Solid TumorsMetastatic Solid TumorsHong Kong - Active not recruitingPHASE3
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
This study is looking into new ways to treat advanced or recurrent womb cancer. We're testing a combination of medicines called durvalumab and olaparib, given after initial chemotherapy, to see if they can help patients live longer and better.
Endometrial NeoplasmsHong Kong - RecruitingPHASE2
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
This study looks at a new drug called futibatinib (also known as TAS-120) for people with advanced bile duct cancer (cholangiocarcinoma). It focuses on patients whose cancer has a specific gene change (FGFR2 fusion or rearrangement) and who have already had standard treatments. The study aims to confirm the drug's benefits at one dose and check a different dose.
Advanced CholangiocarcinomaFGFR2 FusionsGene RearrangementHong Kong - Active not recruitingPHASE3
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
This study is looking at a new tablet, deucrictibant, to see if it can help prevent swelling attacks in people with Hereditary Angioedema (HAE). It includes adults and children aged 12 and over, comparing the new drug to a dummy pill (placebo).
Hereditary Angioedema (HAE)Hong Kong - RecruitingPHASE2
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
This study looks at a new medicine called luspatercept for people with a type of anaemia called alpha-thalassaemia. It aims to see if the medicine is safe and helps reduce the need for blood transfusions.
AnemiaHong Kong - Active not recruitingPHASE3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
This study looks at a new drug, bomedemstat, for essential thrombocythemia (ET). It compares bomedemstat to standard treatments for people whose current medicine, hydroxyurea, isn't working well or causes too many side effects. We want to see if bomedemstat is safer and works better.
Essential ThrombocythemiaHong Kong - Active not recruitingPHASE3
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
This study looks into whether a daily tablet called fenofibrate can help protect the eyes of adults with Type 1 diabetes. It aims to see if this medicine can prevent or slow down eye damage, which is a common problem for people with diabetes.
Type 1 Diabetes MellitusDiabetic RetinopathyDiabetic NephropathiesHong Kong - Active not recruitingPHASE3
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study looks at a new drug, zongertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares zongertinib to standard treatment to see if it can better slow down cancer growth and improve how long people live without their cancer getting worse.
Lung Cancer, Non-squamous, Non-small CellHong Kong - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
This study compares a new drug, Giredestrant, with standard hormone therapy for early breast cancer. It's for people with a specific type of breast cancer (ER-positive, HER2-negative) who have already had surgery.
Early Breast CancerHong Kong - Active not recruitingPHASE3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This study is looking at two new drugs, durvalumab and tremelimumab, for advanced lung cancer. It compares them to standard chemotherapy. Researchers want to see if the new combination helps people live longer and is safe as a first treatment for this type of cancer.
Non Small Cell Lung Carcinoma NSCLCHong Kong - RecruitingPHASE3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
This study looks at new medicines, retatrutide and tirzepatide, for adults with a type of fatty liver disease called MASLD. It aims to see if these drugs can help prevent serious liver problems. Some participants will receive a dummy drug (placebo) to compare.
Metabolic Dysfunction-Associated Steatotic Liver DiseaseHong Kong - Active not recruitingPHASE3
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
This study is looking into a new treatment called inebilizumab for a condition called IgG4-Related Disease. It aims to see if this treatment can stop flare-ups of the disease and if it's safe to use.
IgG4 Related DiseaseHong Kong - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerHong Kong - Active not recruitingPHASE3
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This study is testing a new drug, MRTX849 (adagrasib), for advanced lung cancer with a specific gene change (KRAS G12C). It compares it to a standard treatment, docetaxel, for people whose cancer has already been treated.
Metastatic Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerHong Kong - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Hong Kong - Active not recruitingPHASE3
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
This study is looking into a new drug, zipalertinib, for people with a certain type of lung cancer (NSCLC) in its early stages. It compares zipalertinib with standard chemotherapy to a dummy pill (placebo) with standard chemotherapy after surgery.
Lung CancerAdjuvantPost-surgicalEGFRHong Kong - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
This study is testing a new medicine, Pegozafermin, for people with a severe liver condition called MASH with cirrhosis. It will check how well the medicine works and if it's safe compared to a dummy medicine.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated CirrhosisHong Kong - RecruitingPHASE3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
This study is testing a new drug, Elacestrant, against standard hormone treatments for early breast cancer. It's for men and women whose cancer is ER-positive and HER2-negative, and has a high chance of coming back. The aim is to see if Elacestrant works better.
Breast CancerHong Kong - Active not recruitingPHASE3
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
This study is looking at a new medicine called acalabrutinib for chronic lymphocytic leukaemia (CLL). It compares acalabrutinib to usual treatments to see which works best for people whose CLL has come back or hasn't responded to previous treatment.
Chronic Lymphocytic LeukemiaHong Kong - Active not recruitingPHASE3
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
This study is testing a new medicine called sibeprenlimab for a kidney disease called IgA nephropathy (IgAN). It aims to see if the medicine can reduce protein in the urine and protect kidney function over time, compared to a dummy medicine.
Immunoglobulin A NephropathyHong Kong - Active not recruitingPHASE3
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
This study looks at a new daily pill, enlicitide decanoate, for people at high risk of heart problems like heart attacks or strokes. It aims to see if this pill can help reduce these serious events safely, compared to a dummy pill.
ArteriosclerosisHypercholesterolaemiaHong Kong - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
Non Small Cell Lung Cancer NSCLCHong Kong - Active not recruitingPHASE3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
This study is looking at a new medicine called milvexian to see if it can help prevent another stroke in people who have recently had a mini-stroke or a type of stroke called an ischemic stroke.
Ischemic Stroke; Ischemic Attack, TransientHong Kong - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisHong Kong - Active not recruitingPHASE2
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
This study is checking if the benefits of bepirovirsen for Hepatitis B last over time. It's for people who previously took part in a bepirovirsen trial and showed good results. No new treatment is given in this follow-up study, just monitoring.
Hepatitis BHong Kong